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Abstract
Osteoprotegerin (OPG) is a prime regulator of bone remodel-
ling under both physiological and pathological conditions. Its 
role is strictly related to the receptor activator of nuclear-factor 
(NF)-κB ligand (RANKL), which is also produced by osteoblasts. 
RANKL is a main activator of osteoclasts’ differentiation during 
bone resorption, and OPG is a decoy receptor for RANKL, which 
inhibits osteoclast differentiation by interrupting interactions 
between RANKL and its receptor (RANK).
OPG is produced by osteoclasts as well as by stromal, haemato-
poietic (megakaryocytes) or endothelial cells. Lymphocyte-deri-
ved cytokines also play a critical role during bone metabolism 
and OPG-regulated immunological stimulation. IL-4 and IL-13, 
T helper 2 (Th2) cytokines produced by antigen-activated T cells 
induce OPG production by osteoblasts. The RANK/RANKL sys-
tem is also implicated in dendritic cell-T lymphocyte interac-
tions. Thus, dendritic cell survival, T lymphocyte activation, as 
well as B lymphocyte development, maturation and function 
are regulated by OPG. On the other hand, some clinical data 
indicate that OPG levels are strong and independent predic-
tors of cardiovascular disease (coronary artery calcification and 
hypertension), which suggests that OPG may play a regulatory 
role in cardiac pathology and vascular remodelling. 
In this article, the current view of the role of OPG as a new 
biomarker or prognostic parameter in cardiovascular disease 
will be presented.
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Streszczenie
Osteoprotegeryna (OPG) jest głównym regulatorem przebudo-
wy kości w warunkach fizjologicznych i stanach chorobowych. 
Jej aktywność jest regulowana przez układ aktywatora recep-
tora dla czynnika jądrowego (NF)-κB i jego liganda (RANKL). 
RANKL jest głównym aktywatorem różnicowania i osteoklasto-
genezy podczas resorpcji kości, a OPG jest receptorem-atra-
pą, który hamuje różnicowanie osteoklastów przez blokowa-
nie oddziaływań między ligandem RANKL a jego receptorem 
(RANK). Osteoprotegeryna jest produkowana przez komórki 
macierzy, komórki hematopoetyczne (megakariocyty) i komór-
ki śródbłonka. Zależne od limfocytów cytokiny również odgry-
wają krytyczną rolę w metabolizmie kości i regulowanej przez 
OPG stymulacji układu odpornościowego. Interleukina 4 (IL-4) 
i IL-13, T helper 2 (Th2) są to cytokiny produkowane przez ak-
tywowane antygenem komórki T, które indukują w osteobla-
stach ekspresję OPG. Oś RANK/RANKL jest również związana 
z odziaływaniami między komórkami dendrytycznymi a limfo-
cytami T. Aktywność komórek dendrytycznych, aktywacja lim-
focytów T i dojrzewanie oraz funkcja limfocytów B są poten-
cjalnie regulowane przez OPG.
Z drugiej strony, najnowsze badania kliniczne pokazują, że 
OPG jest silnym i niezależnym wskaźnikiem prognostycznym 
chorób układu krążenia (zwapnień tętnic wieńcowych i nad-
ciśnienia), co sugeruje, że OPG może również odgrywać rolę 
regulatora w patologii serca i przebudowie naczyń. 
Niniejszy artykuł komentuje aktualny stan wiedzy na temat 
zastosowania OPG jako biomarkera i parametru prognostycz-
nego chorób układu krążenia.
Słowa kluczowe: biomarkery przebudowy kostnej, choroby ukła-
du krążenia, komórki dendrytyczne, osteoprotegeryna, zapalenie. 
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The first reference to the role of osteoprotegerin (OPG) 
in cardiovascular disease was made by Jono et al. in 2002 
[1]. They documented that serum OPG levels are associated 
with the progression and the severity of coronary artery di-
sease evaluated by coronary angiography. In the past, there 
was no information about the main sources and regulatory 
mechanism of OPG on the cardiovascular system. Our view 
about its role has significantly changed since then [2, 3].
The OPG/RANK/RANKL triad
OPG is a prime regulator of bone remodelling and may 
exert a substantial influence on the severity of cardiova-
scular disease [4, 5]. OPG operates as a decoy receptor by 
blocking the interaction between the receptor activator of 
nuclear-factor-κB ligand (RANKL) and TNF-related apopto-
sis-inducing ligand (TRAIL), as well as their related recep-
tors: RANK and TRAIL-R1/TRAIL-R2 [6, 7]. OPG regulates the 
RANK/RANKL system and protects against bone loss. In op-
position to its protective role, OPG was shown to block TRA-
IL-induced apoptosis, binding of OPG to TRAIL, abolishing 
its anti-osteoclastogenic activity [8]. It was demonstrated 
in a mouse model that OPG-knockout mice (OPG -/-) deve-
loped early-onset osteoporosis and arterial calcification [9]. 
Additionally the restoration of this gene prevented oste-
oporosis progression and arterial calcification [10].
OPG and other cardiovascular risk factors
What is important is that serum OPG levels positively 
correlate with age [1, 4]. Additionally, Vik et al. observed in 
the general population that age and sex have a differential 
impact on the association between OPG and carotid inti-
ma media thickness (CIMT) [11]. CIMT analysis of carotid 
plaque prevalence showed that after adjustment for age, 
gender and the “classical” risk factors (i.e. smoking, systolic 
blood pressure, BMI, total cholesterol, HDL cholesterol) the 
strength of association between OPG and de novo plaque 
formation or their area progression is significantly reduced 
(mainly in men) [11]. The distribution of male sex across 
tertiles of OPG is significantly reduced in the general popu-
lation; however, age distribution among female and male 
subjects is similar [11, 12]. Taking into consideration that 
OPG can act both as an inhibitor or activator of atherosc-
lerosis, these findings may suggest that increased serum 
OPG may inhibit progression of early atherosclerosis in 
younger female subjects. 
Similarly to adiponectin, in non-diabetic subjects OPG 
was significantly decreased in obese as opposed to lean 
ones [13]. In a general population, OPG negatively correla-
ted with body weight, BMI, waist circumference and fasting 
plasma insulin, while positively correlating with insulin 
sensitivity, and glycated haemoglobin levels [12, 13]. Mo-
reover, the distribution of BMI values across OPG tertiles 
is significantly reduced [12]. The relationship between OPG 
and BMI is observed also in loan subjects, where the loss 
of height, mainly associated with age, and caused by chan-
ges of posture, lower muscle strength, decrease in size of 
the intervertebral discs and the development of osteopo-
rosis, is positively associated with OPG levels [14]. These 
data suggest that both bone remodelling, loss of muscle 
strength and mass, and the disease presentation may in-
fluence OPG levels.
In diabetic patients, OPG was significantly elevated in 
patients with increased coronary artery calcification (CAC) 
[15]. OPG levels were also higher in hypertensive patients 
with retinopathy, patients with a high probability of 10-year 
cardiovascular risk, three or more damaged target organs 
(heart, vessels, kidneys) and those with previous episodes 
of ischaemic cardiomyopathy or hypercholesterolaemia 
(odds ratio: 3.33 and 2.91 respectively) [16]. In apparently 
healthy individuals, plasma OPG levels were significantly 
associated with inflammation and arterial hypertension 
[17]. OPG predicts the premature state of CAC in asympto-
matic normotensive individuals and renal function signifi-
cantly contributes to this process both in hypertensive and 
normotensive subjects [18]. Thus OPG can be used as an 
indicator of diabetes- and hypertension-associated vascu-
lar pathologies as well as a predictor of endothelial dys-
function and cardiovascular risk.
Predictive value of OPG levels
A number of prospective studies (the Bruneck Study 
and the Tromsø Study) have shown that the serum OPG 
increase per standard deviation (1.13 ng/mL or 1.38 pmol/L) 
was associated with an increased incidental risk of myocar-
dial infarction, ischaemic stroke or “vascular mortality” in 
crude and adjusted models over a 10-year follow-up period 
[4, 12]. Moreover, in the Tromsø Study (n = 6265) hazard 
ratios with 95% confidence intervals per SD of death due 
to ischaemic heart disease or nonvascular causes were 
as follows: 1.20 (1.11–1.31) and 1.31 (1.22–1.41).This finding 
supports the concept that OPG serum levels may serve as 
a prerequisite in the prognosis of cardiovascular risk.
Protective or pathogenic role of OPG
OPG is produced by osteoclasts as well as by stromal, 
haematopoietic (megakaryocytes) or arterial wall cells (en-
dothelial cells and vascular smooth muscle cells – VSMC) 
[19, 20]. Very recent studies have shown that osteocytes are 
also an important source of RANKL and OPG, with levels si-
milar (or exceeding) to those in osteoblasts; thus they exhi-
bit a greater capacity to control osteoclastogenesis than 
osteoblasts by the canonical Wnt signalling pathway [21]. 
The deleterious effect of OPG on the vascular wall has been 
shown in vitro and in vivo. OPG can promote the adherence 
of neutrophils to endothelial cells [22]. Moreover, angioten-
sin II, platelet-derived growth factor (PDGF), basic fibroblast 
growth factor (bFGF) and proinflammatory cytokines may 
stimulate OPG expression in VSMC [23, 24], thus providing 
evidence for the role of OPG in VSMC senescence and de-
velopment of vascular calcification [25]. This non-specific 
ligand-independent biological activity occurs due to its 
heparin-binding domain [26]. The possible interactions be-
tween vascular, bone and immune cells are schematically 
presented in Figure 1. 
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Lymphocyte-derived cytokines also play a critical role 
during bone metabolism and the OPG-regulated stimula-
tion. Interleukin-4 (IL-4), a pleiotropic immune cytokine 
produced by T lymphocytes, mast cells, basophils and natu-
ral killer cells, induces OPG production by osteoblasts, and 
inhibits osteoclast activity [27]. The RANK/RANKL system is 
also implicated in dendritic cell-T lymphocyte interactions. 
Dendritic cell (DC) survival, T lymphocyte activation and B 
lymphocyte development, maturation and function are re-
gulated by OPG. RANKL is a dendritic cell-stimulating agent, 
which prolongs DC survival and stimulates T cell maturity, 
thereby regulating DC proliferation [28]. 
Despite animal studies generally favouring the protec-
tive role of OPG, predominantly in terms of vascular calci-
fication [9], the latest data support the pathogenic role of 
OPG in the development and progression of atherosclerotic 
lesions [28]. In vivo treatment of ApoE-/- mice with human 
OPG induced signs of fibrosis, and up-regulated the arterial 
expression of TGF-β1, increasing collagen content [29].
Recently, it was demonstrated that OPG regulates not 
only DC survival but also the nature of DC-dependent in-
flammatory responses. OPG treatment reduced the survival 
and cytokine production of DCs obtained from wild-type 
(WT) mice. On the other hand, OPG deficient (OPG KO – 
knockout) mice, developed osteoporosis. Nevertheless, the-
ir DCs survived better than WT DCs, and produced more 
TNF-α, IL-12p40, and IL-23 cytokines than WT DCs in re-
sponse to Escherichia coli LPS [30].
OPG as a therapeutic target
Intervention studies on animal models suggest that 
OPG deficiency promotes atherogenesis and arterial calci-
fication [9, 31]. However, exogenous OPG supplementation 
does not change atherosclerosis progression but influences 
plaque morphology and collagen content [28, 32]. Angio-
tensin II, which influences OPG expression in VSMC, may 
be used as a potential target in OPG reducing treatment. 
However, in a previous study on serum OPG levels in hyper-
tensive subjects (n = 68 and n = 259), in which about 60% 
of hypertensives were treated with angiotensin-converting 
enzyme (ACE) inhibitors, there was no significant differen-
ce in OPG levels between treated and non-treated subjects 
[16, 17]. Thus, the potential role of ACE inhibitors, the most 
frequently used drugs in standard hypertensive treatment, 
in OPG expression must be revised in larger prospective 
studies.
In conclusion, the OPG/RANK/RANKL triad is a promi-
sing system to be investigated as a marker of calcification- 
related cardiovascular risk and a therapeutic target [33].
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